Alzamend Neuro Inc
ALZN1.820USD
-0.100-5.21%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
6.92MMarket Cap
LossP/E TTM
More Details of Alzamend Neuro Inc Company
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Alzamend Neuro Inc Info
Ticker SymbolALZN
Company nameAlzamend Neuro Inc
IPO dateJun 15, 2021
CEOJackman (Stephan)
Number of employees4
Security typeOrdinary Share
Fiscal year-endJun 15
Address480 Peachtree Road Ne, Second Floor
CityATLANTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30326
Phone18447226333
Websitehttps://alzamend.com/
Ticker SymbolALZN
IPO dateJun 15, 2021
CEOJackman (Stephan)
Company Executives of Alzamend Neuro Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William B. Horne
Mr. William B. Horne
Chairman of the Board
Chairman of the Board
3.33K
--
Mr. David J. Katzoff
Mr. David J. Katzoff
Chief Financial Officer
Chief Financial Officer
615.00
--
Dr. Andrew H. Woo, M.D., Ph.D.
Dr. Andrew H. Woo, M.D., Ph.D.
Independent Director
Independent Director
74.00
--
Mr. Jeffrey Oram
Mr. Jeffrey Oram
Independent Director
Independent Director
74.00
--
Mr. Mark Garland Gustafson
Mr. Mark Garland Gustafson
Independent Director
Independent Director
44.00
--
Mr. Stephan Jackman
Mr. Stephan Jackman
Chief Executive Officer, Director
Chief Executive Officer, Director
33.00
-2.94%
Dr. Lynne Fahey Mcgrath, Ph.D.
Dr. Lynne Fahey Mcgrath, Ph.D.
Independent Director
Independent Director
25.00
-54.55%
Mr. Milton C. Ault, III
Mr. Milton C. Ault, III
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Mr. Kenneth S. (Ken) Cragun
Mr. Kenneth S. (Ken) Cragun
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Henry C.W. Nisser
Mr. Henry C.W. Nisser
Executive Vice President, General Counsel, Director
Executive Vice President, General Counsel, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William B. Horne
Mr. William B. Horne
Chairman of the Board
Chairman of the Board
3.33K
--
Mr. David J. Katzoff
Mr. David J. Katzoff
Chief Financial Officer
Chief Financial Officer
615.00
--
Dr. Andrew H. Woo, M.D., Ph.D.
Dr. Andrew H. Woo, M.D., Ph.D.
Independent Director
Independent Director
74.00
--
Mr. Jeffrey Oram
Mr. Jeffrey Oram
Independent Director
Independent Director
74.00
--
Mr. Mark Garland Gustafson
Mr. Mark Garland Gustafson
Independent Director
Independent Director
44.00
--
Mr. Stephan Jackman
Mr. Stephan Jackman
Chief Executive Officer, Director
Chief Executive Officer, Director
33.00
-2.94%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 25
Updated: Thu, Dec 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
2.40%
Ault (Milton C III)
2.10%
The Vanguard Group, Inc.
0.57%
Geode Capital Management, L.L.C.
0.54%
Clearstead Advisors LLC
0.26%
Other
94.12%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
2.40%
Ault (Milton C III)
2.10%
The Vanguard Group, Inc.
0.57%
Geode Capital Management, L.L.C.
0.54%
Clearstead Advisors LLC
0.26%
Other
94.12%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.04%
Individual Investor
2.17%
Investment Advisor/Hedge Fund
0.80%
Hedge Fund
0.04%
Other
93.94%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
23
147.62K
3.88%
+133.74K
2025Q3
36
147.62K
0.41%
+144.84K
2025Q2
37
3.06K
2.14%
-4.84K
2025Q1
40
7.89K
2.09%
-7.42K
2024Q4
44
12.59K
1.04%
+7.91K
2024Q3
43
4.68K
1.18%
+454.00
2024Q2
48
4.22K
6.08%
-77.00
2024Q1
51
4.30K
6.34%
-536.00
2023Q4
57
4.16K
6.53%
-507.00
2023Q3
59
4.67K
7.19%
+118.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
DRW Securities, LLC
91.25K
2.4%
+91.25K
--
Sep 30, 2025
Ault (Milton C III)
79.97K
2.1%
-1.85K
-2.26%
Dec 23, 2025
The Vanguard Group, Inc.
21.62K
0.57%
+21.02K
+3503.33%
Sep 30, 2025
Geode Capital Management, L.L.C.
20.58K
0.54%
+20.58K
--
Sep 30, 2025
Clearstead Advisors LLC
10.00K
0.26%
+10.00K
--
Sep 30, 2025
UBS Financial Services, Inc.
2.08K
0.05%
+1.17K
+130.04%
Sep 30, 2025
Tower Research Capital LLC
1.61K
0.04%
+809.00
+101.51%
Sep 30, 2025
Katzoff (David J)
615.00
0.02%
--
--
Oct 07, 2025
BlackRock Institutional Trust Company, N.A.
437.00
0.01%
-4.00
-0.91%
Sep 30, 2025
Woo (Andrew H)
74.00
0%
--
--
Jul 22, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 08, 2025
Merger
9→1
Jul 12, 2024
Merger
10→1
Jul 12, 2024
Merger
10→1
Jul 12, 2024
Merger
10→1
Jul 12, 2024
Merger
10→1
Oct 30, 2023
Merger
15→1
Date
Type
Ratio
May 08, 2025
Merger
9→1
Jul 12, 2024
Merger
10→1
Jul 12, 2024
Merger
10→1
Jul 12, 2024
Merger
10→1
Jul 12, 2024
Merger
10→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Alzamend Neuro Inc?
The top five shareholders of Alzamend Neuro Inc are:
DRW Securities, LLC holds 91.25K shares, accounting for 2.40% of the total shares.
Ault (Milton C III) holds 79.97K shares, accounting for 2.10% of the total shares.
The Vanguard Group, Inc. holds 21.62K shares, accounting for 0.57% of the total shares.
Geode Capital Management, L.L.C. holds 20.58K shares, accounting for 0.54% of the total shares.
Clearstead Advisors LLC holds 10.00K shares, accounting for 0.26% of the total shares.
DRW Securities, LLC holds 91.25K shares, accounting for 2.40% of the total shares.
Ault (Milton C III) holds 79.97K shares, accounting for 2.10% of the total shares.
The Vanguard Group, Inc. holds 21.62K shares, accounting for 0.57% of the total shares.
Geode Capital Management, L.L.C. holds 20.58K shares, accounting for 0.54% of the total shares.
Clearstead Advisors LLC holds 10.00K shares, accounting for 0.26% of the total shares.
What are the top three shareholder types of Alzamend Neuro Inc?
The top three shareholder types of Alzamend Neuro Inc are:
DRW Securities, LLC
Ault (Milton C III)
The Vanguard Group, Inc.
DRW Securities, LLC
Ault (Milton C III)
The Vanguard Group, Inc.
How many institutions hold shares of Alzamend Neuro Inc (ALZN)?
As of 2025Q4, 23 institutions hold shares of Alzamend Neuro Inc, with a combined market value of approximately 147.62K, accounting for 3.88% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 3.47%.
What is the biggest source of revenue for Alzamend Neuro Inc?
In --, the -- business generated the highest revenue for Alzamend Neuro Inc, amounting to -- and accounting for --% of total revenue.
